HIV, HCV, and health-related harms among women who inject drugs: Implications for prevention and treatment

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue , 2015, Pages S176-S181

  Iversen, Jenny ^a   Page, Kimberly ^b   Madden, Annie ^c   Maher, Lisa ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c Australian Injecting and Illicit Drug Users' League (AIVL)   (Australia)

Author keywords

Harm reduction; HCV; Health; HIV; Women who inject drugs

Indexed keywords

ABSCESS; ARTICLE; CELLULITIS; CHILD CARE; ENDOCARDITIS; FEMALE; HARM REDUCTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MENTAL HEALTH; NAMED GROUPS BY SEXUALITY; PHYSICAL VIOLENCE; PREGNANCY; PRIORITY JOURNAL; PROSTITUTION; REPRODUCTIVE HEALTH; SEPSIS; SEXUAL VIOLENCE; SOCIAL DISCRIMINATION; STIGMA; WOMEN WHO INJECT DRUGS; COMORBIDITY; COMPLICATION; HEALTH; HEALTH SERVICE; HEPATITIS B; HIV INFECTIONS; PUBLIC HEALTH; SUBSTANCE ABUSE; VULNERABLE POPULATION; WOMEN'S HEALTH;

COMORBIDITY; FEMALE; GLOBAL HEALTH; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; NATIONAL HEALTH PROGRAMS; SUBSTANCE ABUSE, INTRAVENOUS; VULNERABLE POPULATIONS; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 84964695765     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000659     Document Type: Article

References (70)

1. Hunt K, Annandale E. Relocating gender and morbidity: examining men's and women's health in contemporary Western societies. Introduction to Special Issue on Gender and Health. Soc Sci Med. 1999;48:1-5.
2. World Economic Forum. The Global Gender Gap Report. 2014. Available at: http://reports.weforum.org/global-gender-gap-report-2014/. Accessed January 27, 2015.
3. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733-1745.
4. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1564-1574.
5. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-583.
6. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(suppl 1):S6-S9.
7. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18:352-358.
8. United Nations Office on Drugs and Crime. Women Who Inject Drugs and HIV: Addressing Specific Needs. 2014. Available at: http://www.unodc.org/documents/hiv-aids/publications/WOMEN-POLICY-BRIEF2014.pdf. Accessed January 27, 2015.
9. El-Bassel N, Wechsberg WM, Shaw SA. Dual HIV risk and vulnerabilities among women who use or inject drugs: no single prevention strategy is the answer. Curr Opin HIV AIDS. 2012;7:326-331.
10. El-Bassel N, Shaw SA, Dasgupta A, et al. Drug use as a driver of HIV risks: re-emerging and emerging issues. Curr Opin HIV AIDS. 2014;9:150-155.
11. Des Jarlais DC, Feelemyer JP, Modi SN, et al. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend. 2012;124:95-107.
12. Azim T, Bontell I, Strathdee SA. Women, drugs and HIV. Int J Drug Policy. 2015;26(suppl 1):S16-S21.
13. Shannon K, Csete J. Violence, condom negotiation, and HIV/STI risk among sex workers. JAMA. 2010;304:573-574.
14. El-Bassel N, Gilbert L, Wu E, et al. HIV and intimate partner violence among methadone-maintained women in New York City. Soc Sci Med. 2005;61:171-183.
15. Joint United Nations Programme on HIV/AIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Available at: http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed January 27, 2015.
16. UN Women. A Gender Perspective on the Impact of Drug Use, the Drug Trade, and Drug Control Regimes. 2014. Available at: http://www.unodc.org/documents/ungass2016//Contributions/UN/Gender-and-Drugs---UN-Women-Policy-Brief.pdf. Accessed January 27, 2015.
17. Asher AK, Hahn JA, Couture MC, et al. People who inject drugs, HIV risk, and HIV testing uptake in sub-Saharan Africa. J Assoc Nurses AIDS Care. 2013;24:e35-e44.
18. Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109-120.
19. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48:353-367.
20. Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005;40(suppl 5):S304-S312.
21. Iversen J, Grebely J, Topp L, et al. Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999-2011. J Viral Hepat. 2014;21:198-207.
22. Miller CL, Wood E, Spittal PM, et al. The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr. 2004;36:743-749.
23. Iversen J, Wand H, Gonnermann A, et al; collaboration of Australian Needle, Syringe Programs. Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. Int J Drug Policy. 2010;21:471-476.
24. Tracy D, Hahn JA, Fuller Lewis C, et al. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open. 2014;4:e004988.
25. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med. 2001;161:1281-1288.
26. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186:1558-1564.
27. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101:1499-1508.
28. Frajzyngier V, Neaigus A, Gyarmathy VA, et al. Gender differences in injection risk behaviors at the first injection episode. Drug Alcohol Depend. 2007;89:145-152.
29. Morris MD, Evans J, Montgomery M, et al. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. PLoS One. 2014;9:e109282.
30. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376:355-366.
31. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367-387.
32. Weiss JJ, Osorio G, Ryan E, et al. Prevalence and patient awareness of medical comorbidities in an urban AIDS clinic. AIDS Patient Care STDS. 2010;24:39-48.
33. Shepard CW, Simard EP, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-125.
34. Pinkham S, Malinowska-Sempruch K. Women, harm reduction and HIV. Reprod Health Matters. 2008;16:168-181.
35. Spijkerman IJ, van Ameijden EJ, Mientjes GH, et al. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol. 1996;49:1149-1154.
36. Hope V, Kimber J, Vickerman P, et al. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis. 2008;8:120.
37. Smith DK, Gardner LI, Phelps R, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health. 2003;80:676-688.
38. Topp L, Iversen J, Conroy A, et al. Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. Aust N Z J Public Health. 2008;32:34-37.
39. El-Bassel N, Gilbert L, Witte S, et al. Couple-based HIV prevention in the United States: advantages, gaps, and future directions. J Acquir Immune Defic Syndr. 2010;55(suppl 2):S98-S101.
40. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49:1433-1440.
41. Tuchman E. Women and addiction: the importance of gender issues in substance abuse research. J Addict Dis. 2010;29:127-138.
42. Rowan-Szal GA, Chatham LR, Joe GW, et al. Services provided during methadone treatment. A gender comparison. J Subst Abuse Treat. 2000;19:7-14.
43. Topp L, Hudson SL, Maher L. Mental health symptoms among street-based psychostimulant injectors in Sydney's Kings Cross. Subst Use Misuse. 2010;45:1180-1200.
44. Magnus M, Kuo I, Phillips G II, et al. Differing HIV risks and prevention needs among men and women injection drug users (IDU) in the District of Columbia. J Urban Health. 2013;90:157-166.
45. Johnson SD, Cottler LB, O'Leary CC, et al. The association of trauma and PTSD with the substance use profiles of alcohol- and cocaine-dependent out-of-treatment women. Am J Addict. 2010;19:490-495.
46. Li Y, Marshall CM, Rees HC, et al. Intimate partner violence and HIV infection among women: a systematic review and meta-analysis. J Int AIDS Soc. 2014;17:18845.
47. Roberts A, Mathers BM, Degenhardt L. Women Who Inject Drugs: A Review of Their Risks, Experiences and Needs. 2010. Available at: https://www.unodc.org/documents/hiv-aids/Women-who-inject-drugs.pdf Accessed January 27, 2015.
48. El-Bassel N, Gilbert L, Witte S, et al. Intimate partner violence and HIV among drug-involved women: contexts linking these two epidemics - challenges and implications for prevention and treatment. Subst Use Misuse. 2011;46:295-306.
49. Morris MD, Lemus H, Wagner KD, et al. Factors associated with pathways toward concurrent sex work and injection drug use among female sex workers who inject drugs in northern Mexico. Addiction. 2013;108:161-170.
50. Maher L. Hidden in the light: occupational norms among crack-using street-level sex workers. J Drug Issues. 1996;26:143-173.
51. Thorne C, Semenenko I, Pilipenko T, et al; Ukraine European Collaborative Study Group. Progress in prevention of mother-to-child transmission of HIV infection in Ukraine: results from a birth cohort study. BMC Infect Dis. 2009;9:40.
52. De Vuyst H, Lillo F, Broutet N, et al. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17:545-554.
53. Jay N, Moscicki AB. Human papillomavirus infections in women with HIV disease: prevalence, risk, and management. AIDS Read. 2000;10:659-668.
54. Weber AE, Tyndall MW, Spittal PM, et al. High pregnancy rates and reproductive health indicators among female injection-drug users in Vancouver, Canada. Eur J Contracept ReprodHealth Care. 2003;8:52-58.
55. Duff P, Shoveller J, Zhang R, et al. High lifetime pregnancy and low contraceptive usage among sex workers who use drugs - an unmet reproductive health need. BMC Pregnancy Childbirth. 2011;11:61.
56. Maher L. Sexed Work: Gender, Race and Resistance in a Brooklyn Drug Market. Oxford, United Kingdom: Oxford University Press; 1997. reprinted 2002.
57. UNODC, UNAIDS. Women and HIV in Prison Settings. 2008. Available at: http://www.unodc.org/documents/hiv-aids/Women-in-prisons.pdf Accessed January 27, 2015.
58. Lakobishvili L. Cause for Alarm: The Incarceration of Women for Drug Offences in Europe and Central Asia, and the Need for Legislative and Sentencing Reform. International Harm Reduction Association, 2012. Available at: http://www.ihra.net/files/2012/03/11/HRI-WomenInPrisonReport.pdf. Accessed January 27, 2015.
59. Bureau of Justice Statistics. National Prisoner Statistics Program, National Corrections Reporting Program, Survey of Inmates in State Correctional Facilities. 2014. Available at: http://www.bjs.gov/datacollection.cfm. Accessed March 25, 2015.
60. UNODC, WHO Europe. Women's Health in Prison. Correcting Gender Inequity in Prison Health. 2009. Available at: http://www.euro.who.int/-data/assets/pdf-file/0004/76513/E92347.pdf?ua=1. Accessed January 27, 2015.
61. Jurgens R. Out of sight, out of mind: harm reduction in prisons and other places of detention. In: Cook C, ed. The Global State of Harm Reduction: Key Issues for Broadening the Response: International Harm Reduction Association; 2010:105-112. Available at: http://www.ihra.net/global-state-of-harm-reduction-2010. Accessed January 27, 2015.
62. UNODC, ILO, UNDP, WHO, UNAIDS. HIV Prevention, Treatment and Care in Prisons and Other Closed Settings: A Comprehensive Package of Interventions. 2013. Available at: http://www.who.int/hiv/pub/prisons/prisons-package.pdf?ua=1. Accessed January 27, 2015.
63. Baral S, Beyrer C, Muessig K, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:538-549.
64. Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88:188-196.
65. WHO, UNODC, UNAIDS. Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users (2012 Revision). 2012. Available at: http://apps.who.int/iris/bitstream/10665/77969/1/9789241504379-eng.pdf?ua=1. Accessed January 27, 2015.
66. UNAIDS. The Gap Report: People Who Inject Drugs. 2014. Available at: http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/gapreport12pops/05-Peoplewhoinjectdrugs.pdf. Accessed January 27, 2015.
67. Taplin S, Mattick RP. The nature and extent of child protection involvement among heroin-using mothers in treatment: high rates of reports, removals at birth and children in care. Drug Alcohol Rev. 2015;34:31-37.
68. Perez-Montejano R, Finch E, Wolff K. FC03-05 - An evaluation of service provision by community drug treatment services for opioid dependent pregnant drug users in England and Wales. Eur Psychiatry. 2011;26:1826.
69. Grella CE. From generic to gender-responsive treatment: changes in social policies, treatment services, and outcomes of women in substance abuse treatment. J Psychoactive Drugs. 2008;40(suppl 5):S327-S343.
70. United Nations Developoment Programme. Checklist for Integrating Gender into the New Funding Model of the Global Fund to Fight AIDS, TB and Malaria. 2014. Available at: http://www.pk.undp.org/content/undp/en/home/librarypage/hiv-aids/checklist-for-integrating-gender-into-the-new-funding-model-of-t.html. Accessed January 27, 2015.